Therapeutic Option for Hepatitis B and C: a French Cohort

Trial Profile

Therapeutic Option for Hepatitis B and C: a French Cohort

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Sofosbuvir (Primary) ; Antivirals; Daclatasvir; Ribavirin; Simeprevir
  • Indications Hepatitis B; Hepatitis C
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms HEPATHER
  • Most Recent Events

    • 04 Oct 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2022.
    • 10 Sep 2016 Results analysing efficacy and safety of daclatasvir-sofosbuvir combination in HCV genotype 1 infected patients (n=768) published in the Journal of Hepatology.
    • 17 Aug 2016 Planned End Date changed from 1 Aug 2022 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top